戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eous breathing (prevented by a neuromuscular blocking agent).
2 ded medications (aspirin and beta-adrenergic blocking agents).
3 id DCs that secrete the potent costimulation blocking agent.
4 hexamethonium (10 mg/kg, i.v.), a ganglionic blocking agent.
5 DS and had been treated with a neuromuscular blocking agent.
6 ses the impact of a cell cycle mitotic phase blocking agent.
7 d without injecting pharmacologic doses of a blocking agent.
8 d, or when using bovine serum albumin as the blocking agent.
9 FU/ml was achieved when 2% BSA was used as a blocking agent.
10 th myasthenia gravis receiving neuromuscular-blocking agents.
11 in a 1: 1 ratio with steroidal neuromuscular blocking agents.
12 lmonary fibroblasts were incubated with CTGF blocking agents.
13 ors are affected by the use of neuromuscular blocking agents.
14 ectively encapsulate steroidal neuromuscular blocking agents.
15 anslate these insights into prototypical DQ2 blocking agents.
16 ing different non-depolarizing neuromuscular blocking agents.
17 eiving continuous infusions of neuromuscular-blocking agents.
18 r nonresponders (n = 12) to therapy with TNF blocking agents.
19 may affect the outcome of treatment with TNF blocking agents.
20  nor the varying properties of different TNF-blocking agents.
21 xtracellular ion concentrations or potential blocking agents.
22 anding barriers to the effective use of beta-blocking agents.
23 , are relevant for the design of therapeutic blocking agents.
24 lity to block this passage with gap junction blocking agents.
25 channel in the context of ion permeation and blocking agents.
26 tubation in patients receiving neuromuscular-blocking agents.
27 ination with variable doses of neuromuscular blocking agents.
28  heart failure patients with beta-adrenergic blocking agents.
29 continuation of treatment with neuromuscular blocking agents.
30 ceiving continuous infusion of neuromuscular-blocking agents.
31 nt as demonstrated by studies with secretion blocking agents.
32 surgery or were treated with calcium channel blocking agents.
33 pha-2 adrenergic agonists or beta adrenergic blocking agents.
34 , shared to some extent with calcium channel blocking agents.
35 ing the treatment of heart failure with beta-blocking agents.
36 atients receiving infusions of neuromuscular-blocking agents.
37 g continuous administration of neuromuscular-blocking agents.
38 retion led to successful treatment with IL-1-blocking agents.
39  reaction, importantly, without the need for blocking agents.
40 who are increasingly treated with complement blocking agents.
41 ut beta-blockers or renin-angiotensin system blocking agents.
42 nts associated with the use of neuromuscular blocking agents.
43  respond dramatically to treatment with IL-1 blocking agents.
44 80 mg/dL in patients receiving neuromuscular-blocking agents.
45 , 2% BSA in 1.0 x 10-2 M, pH 7.4, PBS as the blocking agent, 0.5 mL/h as the sample flow rate, 1.0 x
46 han long-acting intraoperative neuromuscular blocking agents (1 RCT) reduce risk.
47         Paradoxically, the potassium channel blocking agent 4-aminopyridine (4AP) can sometimes cause
48 001) and more often received beta-adrenergic blocking agents (49% vs. 14%, p < 0.0001).
49    BALB/c mice were given small molecule GRP blocking agent 77427, or GRP blocking antibody 2A11, bef
50 ng enzyme inhibitors or angiotensin receptor blocking agents 85.3% versus 77.4% (AOR, 1.62; 95% CI, 1
51 of xemilofiban, an oral platelet GP IIb/IIIa blocking agent, administered to patients after percutane
52 col should include guidance on neuromuscular-blocking agent administration in patients undergoing the
53 or the subset of patients on beta-adrenergic blocking agents after CABG, there was a trend toward les
54     Encouraging early clinical results using blocking agents against components of the PD-1 pathway h
55 s corticosteroids and neuromuscular junction-blocking agents, although the exposure to the latter dru
56 e, treatment with the interleukin-1 receptor blocking agent anakinra 100 mg/d was started.
57  myocarditis with the interleukin-1 receptor blocking agent anakinra.
58 sociation between receipt of a neuromuscular blocking agent and in-hospital mortality among mechanica
59 alcium channel blockers if already on a beta-blocking agent and rate-limiting calcium channel blocker
60            Whether the type of neuromuscular blocking agent and the duration of use are important det
61 (age 4 months), treated with a neuromuscular blocking agent and ventilated: control, hyperoxia-treate
62 dical treatments, including alpha-adrenergic blocking agents and 5 alpha-reductase inhibitors mean th
63   Without their use, dosing of neuromuscular blocking agents and anticholinesterases is often inappro
64 derivatives can be ablated by Ca(2+)-channel blocking agents and by the calcium chelator 1,2-bis(o-am
65                  The newer vasodilating beta-blocking agents and calcium antagonists appear to be met
66 treatment with nondepolarizing neuromuscular blocking agents and corticosteroids in the intensive car
67                         Using both CTLA-4/B7-blocking agents and CTLA-4-deficient T cells, we found t
68 lth outcomes associated with beta-adrenergic blocking agents and diltiazem treatment for unstable ang
69 als (n = 23) using pretreatment with various blocking agents and doses.
70 amined the association between neuromuscular blocking agents and ICU-acquired weakness, critical illn
71       The relationship between neuromuscular blocking agents and neuromuscular dysfunction acquired i
72 s a modest association between neuromuscular blocking agents and neuromuscular dysfunction acquired i
73 ot show an association between neuromuscular blocking agents and neuromuscular dysfunction acquired i
74 mice were simultaneously exposed to activity-blocking agents and neurotrophins for 2 weeks.
75 lso associated with the use of neuromuscular blocking agents and prolonged mechanical ventilation, su
76 ous ELISA assay involves multiple steps with blocking agents and secondary reporters that ultimately
77 elationship between the use of neuromuscular blocking agents and skeletal muscle weakness.
78 l the potential use of porins as targets for blocking agents and suggest that polyamines may act as e
79 is of the different orders of potency of the blocking agents and the differential response to 1-EBIO
80  been proposed based on the use of molecular blocking agents and transgenic animals to elucidate dise
81 7 years) who were not taking beta-adrenergic blocking agents and were referred for symptom-limited ex
82 operitoneal fibrosis include the use of beta-blocking agents, and connective tissue disease processes
83         Amiodarone, sedation, sodium channel-blocking agents, and ventricular pacing were effective i
84 acologic probes (lidocaine [a sodium channel blocking agent] and cesium [an outward potassium channel
85          The use of aspirin, beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitor
86  Does nurse-led titration of beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitor
87                                Neuromuscular blocking agents are commonly used in critical care.
88  capability when aspirin and beta-adrenergic blocking agents are given appropriately and transfer is
89                                Neuromuscular blocking agents are routinely used in the operating room
90           Although currently available Notch-blocking agents are showing anti-tumor activity in precl
91                                         beta-Blocking agents are the mainstay of treatment.
92 nd protocols could ensure that neuromuscular blocking agents are used and monitored appropriately.
93                              Beta-adrenergic blocking agents are used in most patients for symptomati
94 s problem, many protein and surfactant-based blocking agents are used.
95 data prompt the future development of an FSH-blocking agent as a means of uncoupling bone formation a
96 r patients with AMI, such as beta-adrenergic blocking agents, aspirin and immediate reperfusion thera
97 al variable found receipt of a neuromuscular blocking agent associated with a 4.3% (95% CI, -11.5%, 1
98 ethylmethanethiosulfonate (AEMTS) as a thiol-blocking agent at 25 degrees C and pH 8.0.
99  to a peripheral site of action of the nAChR-blocking agents at the neuromuscular junction (NMJ), bec
100 bility of four nondepolarizing neuromuscular blocking agents (atracurium, gallamine, metocurine, and
101 was to assess the effect of the inflammasome blocking agents BAY 11-7082 (30 mg/kg, i.p.) and Brillia
102           1) We suggest that a neuromuscular-blocking agent be administered by continuous intravenous
103 ests that a reduced dose of an neuromuscular-blocking agent be used for patients with myasthenia grav
104            10) We suggest that neuromuscular-blocking agents be discontinued at the end of life or wh
105 linical practice suggests that neuromuscular-blocking agents be discontinued prior to the clinical de
106 ctic ester, followed by incorporation of the blocking agent bovine serum albumin.
107 tan, and intravenous injection of a ganglion blocking agent, but not an arginine vasopressin V1 recep
108 ated by hexamethonium, an autonomic ganglion blocking agent, but was abolished by CGRP-(8-37), an ant
109  (23%) who were treated with a neuromuscular blocking agent by hospital day 2.
110  of concomitant medications (beta-adrenergic blocking agents, calcium channel blocking agents or digo
111 A/1LacJ mice that were administered the CD80 blocking agents, called CD80-binding competitive antagon
112 nhibit DC maturation, whereas co-stimulation-blocking agents can also promote the induction of antige
113 luorescent dyes, the presence of these toxic blocking agents can be observed as a decrease in fluores
114              Here we show that transcription-blocking agents can induce phosphorylation of the Ser-15
115                               Sodium channel blocking agents can provide effective protection of axon
116 demonstrate that treatment with inflammasome-blocking agents can significantly reduce the development
117 +, Sr2+, Mg2+, and La3+) and by gap junction blocking agents (carbenoxolone, octanol, heptanol, flufe
118  studies with the alpha- and beta-adrenergic blocking agent carvedilol demonstrated a significant sur
119                    The third-generation beta-blocking agent carvedilol has substantially different ef
120 he use of nondihydropyridine calcium channel blocking agents (CCBs) appears to reduce reinfarction in
121 tudy, we report the efficacy of a novel CD80-blocking agent CD80-competitive antagonist peptide (CD80
122 e the first evidence that a cyclooxygenase 2 blocking agent, celecoxib, possesses strong chemoprevent
123 ffects of the potent selective 5-HT reuptake blocking agent, citalopram (10 mg/kg, i.v.), on local ce
124           However, N-ethylmaleimide, a thiol-blocking agent, completely eliminated its formation.
125 kness and included charges for neuromuscular blocking agents, continuous mechanical ventilation, ICU
126 perative administration of the costimulatory blocking agent CTLA4 immunoglobulin exhibited >100-day s
127 kg), together with the B7-CD28 costimulation blocking agent CTLA4Ig, 7 days before renal transplantat
128    Because most of the familiar Ca2+ channel blocking agents currently used in cardiology, such as ni
129   Dose-response studies with a translational blocking agent demonstrate that the cellular oxidative r
130 genation improved by beta-blockade and beta1-blocking agent did offset the adverse effect of epinephr
131 ce of female gender, greater calcium channel blocking agent, digoxin and diuretic use, lower heart ra
132  over another when calculating neuromuscular-blocking agent doses in obese patients.
133  body weight) when calculating neuromuscular-blocking agents doses for obese patients.
134      Thus, in addition to being an effective blocking agent during the initiation phase, these findin
135                However, use of neuromuscular blocking agents during emergent airway management outsid
136 ith nicotinic acetylcholine receptor (nAChR)-blocking agents [e.g., curare or alpha-bungarotoxin (alp
137                            Several available blocking agents effectively suppressed this erroneous si
138  The short-acting beta1-selective adrenergic blocking agent, esmolol, was administrated during cardio
139 responded dramatically to the sodium channel blocking agent flecainide.
140 ed with that of the classical sodium channel blocking agent, flecainide, which has no recognized mono
141 otected by application of the sodium channel-blocking agent, flecainide.
142                           The effects of the blocking agent, flow rate of samples and substrates, buf
143 lockade are relevant to the choice of a BAFF blocking agent for the treatment of autoimmune and malig
144 atients and have led to the approval of IL-1-blocking agents for a number of autoinflammatory conditi
145               Intensivists use neuromuscular blocking agents for a variety of clinical conditions, in
146 endation on the routine use of neuromuscular-blocking agents for patients undergoing therapeutic hypo
147 l examples of pharmacologically suitable DQ2 blocking agents for the potential treatment of Celiac Sp
148 dings indicate the possible utility of IL-1R-blocking agents for the treatment of ocular inflammatory
149 l therapy with a diuretic or beta-adrenergic blocking agent, for which reductions in morbidity and mo
150 , including their sensitivity to replication-blocking agents, growth defects, and inefficient chromat
151 ing drug reserpine and the adrenergic neuron-blocking agent guanethidine.
152          In addition, the specificity of the blocking agents has been assessed by determining the ext
153       Chronic treatment with beta-adrenergic blocking agents has been shown to improve left ventricul
154 n the clinical pharmacology of neuromuscular blocking agents have advocated routine intraoperative us
155                              Beta-adrenergic blocking agents have been revalidated in recent studies
156                                         beta-Blocking agents have beneficial effects on survival of p
157 ong-term safety of the tumor necrosis factor blocking agents have prompted investigators to take a cl
158  stage gametocytes and identify transmission-blocking agents have, until now, been hindered by a lack
159 e likely to receive aspirin, beta-adrenergic blocking agents, heparin and nitrates (all p < 0.0001).
160                                    Two other blocking agents, heterophilic blocking reagent and immun
161 intravenous administration of the ganglionic blocking agent hexamethonium (5 mg/kg) or an arginine va
162  and non-responses to tumour necrosis factor blocking agents, however, together with the increasing c
163 ent broth media was reported as an effective blocking agent; however, the natural background fluoresc
164 utants - hypersensitivity to the replication blocking agent hydroxyurea (HU).
165 ne, along with potentiation by neuromuscular blocking agents, immobilization, and probably also concu
166                                         Beta-blocking agents improve functional status and reduce mor
167 4-amino-pyridine (4-AP), a potassium channel-blocking agent, improves symptoms in some patients with
168 nd provides a rationale for the use of IL-22-blocking agents in B-cell-mediated autoimmune conditions
169                     The addition of TGF-beta blocking agents in clinical trials of immunotherapies ma
170  These data strongly support testing of PD-1-blocking agents in combination with standard-of-care che
171 such as aspirin, statins and beta-adrenergic blocking agents in conjunction with comprehensive lifest
172     3) We suggest a trial of a neuromuscular-blocking agents in life-threatening situations associate
173 o recommendation on the use of neuromuscular-blocking agents in pregnant patients.
174 tiated by ATP-sensitive K(+) (K-ATP) channel blocking agents in STN neurons but not in dopamine neuro
175 perior blocking efficacy compared with other blocking agents in terms of high signal-to-noise ratio w
176       The use of sedatives and neuromuscular blocking agents in the ICU is positively associated with
177 nt] and cesium [an outward potassium channel blocking agent]) in 26 swine.
178              The application of selective SK blocking agents (including apamin, scyllatoxin and newer
179                         T-cell costimulatory blocking agents inhibit allospecific T-cell responses in
180 This includes the injection of neuromuscular blocking agents into anterior scalene muscles to help co
181 ed in the prone position and a neuromuscular blocking agent is administered, without improvement in h
182 ection, early treatment with a neuromuscular blocking agent is associated with lower in-hospital mort
183 s patches (R(2) > 0.99), suggesting that the blocking agent is closely associated with the channel.
184 e hypothesized that the use of neuromuscular blocking agents is associated with a decreased prevalenc
185 opathy patients treated with beta-adrenergic blocking agents is controversial.
186 kin's battery, by topical application of Na+ blocking agents leads to inhibition or disruption of nor
187             4) We suggest that neuromuscular-blocking agents may be used to manage overt shivering in
188 ls suggest that treatment with neuromuscular blocking agents may improve survival in patients requiri
189 -AW and provides evidence that neuromuscular blocking agents may not be a major cause of weakness in
190  studies have suggested that calcium channel-blocking agents may prevent new coronary lesion formatio
191 our data suggest that therapeutic CD40-CD40L blocking agents may prove efficacious not only in early
192                         However, potent CCR5 blocking agents may select for HIV-1 variants that use a
193 d mechanism for understanding how Na channel-blocking agents may suppress the pathologic, sustained N
194  suppress the sensitivity to the replication-blocking agent methylmethane sulfonate (MMS) in smc6 mut
195 ere reduced by the beta1-adrenergic receptor blocking agent metoprolol (1.5 mg/kg, intravenous), whic
196 to treatment with a beta-adrenergic-receptor blocking agent (metoprolol or carvedilol) or placebo.
197  some pairs of nondepolarizing neuromuscular blocking agents might be more efficacious because the hi
198 ective of chemical structural, neuromuscular blocking agents might produce prolonged paralysis in pre
199 toring and use of sedative and neuromuscular blocking agents, more mechanical ventilation days, and l
200                                    The thiol-blocking agent N-ethylmaleimide was applied in order to
201                             The Ca2+ channel-blocking agents Nd3+ and nifedipine partially inhibited
202 ing use of continuous-infusion neuromuscular blocking agents (NMB) in the intensive care unit (ICU).
203 4 (23%) lacked BSACI compliant neuromuscular blocking agent (NMBA) panels and 17/44 (39%) lacked a NA
204     Eleven patients received a neuromuscular blocking agent (NMBA) without a sedative/analgesic agent
205 anaphylaxis but not exposed to neuromuscular blocking agents (NMBA) were included.
206      Anaphylactic reactions to neuromuscular blocking agents (NMBAs) can be severe and even fatal.
207 on of analgesic, sedative, and neuromuscular blocking agents (NMBAs) for each patient.
208                                Neuromuscular blocking agents (NMBAs) induce dose-dependent muscle rel
209                     Allergy to neuromuscular blocking agents (NMBAs) is the most important caue of pe
210 use of sedatives, opioids, and neuromuscular blocking agents (NMBAs) may delay weaning and prolong in
211 use of allergic anaphylaxis to neuromuscular blocking agents (NMBAs).
212 a, was synchronized with the use of the G2/M blocking agent nocodazole.
213 Our results support the use of VEGF-C/VEGF-D-blocking agents not only to inhibit metastatic progressi
214 of sedative, analgesic, and/or neuromuscular blocking agents; nurse administration of these medicatio
215        Complementary experiments involving a blocking agent of cell wall pores and water root transpo
216 e of monoclonal antibody QCRL-4, a selective blocking agent of the MRP1 pumps.
217 ion with rAd encoding a potent costimulation blocking agent offers promise for therapy of allograft r
218 ry artery disease, nonuse of calcium channel blocking agents, older donor age, posttransplantation cy
219              Subjects taking a hydrogen pump blocking agent (omeprazole) develop bacterial overgrowth
220  to examine the effects of a beta-adrenergic blocking agent on the ischemic response to dobutamine st
221  of specific nonpeptide angiotensin receptor blocking agents on survival after myocardial infarction
222  enzyme (ACE) inhibitors and beta-adrenergic blocking agents on the remodeling process.
223  angina pectoris receiving a beta-adrenergic blocking agent or calcium antagonist, or both.
224 -adrenergic blocking agents, calcium channel blocking agents or digoxin).
225 ither timolol, a nonspecific beta adrenergic blocking agent, or with para-aminoclonidine, an alpha-2
226 y more likely to have received neuromuscular blocking agents (p = .004) or propofol (p =.026) for >1
227 s with first MI, patients on beta-adrenergic blocking agents, patients with LVEF < or =30%, patients
228 or vasopressors, sedatives, or neuromuscular blocking agents, percentage of patients that achieved un
229                  Tumor necrosis factor-alpha blocking agents play an important role in the treatment
230 An analysis using the hospital neuromuscular blocking agent-prescribing rate as an instrumental varia
231            Phentolamine, an alpha-adrenergic blocking agent, prevents the C75-induced increases of sk
232 ravenous injections of the beta-adrenoceptor blocking agent, propranolol.
233               Novel retinoic acid metabolism blocking agents (RAMBAs) have been synthesized and chara
234 re sedative, analgesic, and/or neuromuscular blocking agent, range 1-9 drugs, mean 2.5 (+1.5) drugs.
235 iving a continuous infusion of neuromuscular-blocking agent receive a structured physiotherapy regime
236                                         Beta-blocking agents reduce the risk of hospitalization and d
237                                          All blocking agents reduced the number of N-cadherin-positiv
238 blockade: encapsulation of the neuromuscular blocking agent, resulting in inactivation.
239       A concentration response curve of this blocking agent revealed a half maximal inhibitory concen
240 in immature female rats using estradiol as a blocking agent revealed specific uptake of [18F]FEDPN in
241  hypoxia exposure, and the use of a ganglion blocking agent should inhibit activity within all branch
242 0-year period, increasing evidence that beta-blocking agents should or actually did improve the natur
243 terference with the Tie-2 pathway by diverse blocking agents such as soluble Tie-2 receptors, anti-Ti
244 cluded from most trials of immune checkpoint blocking agents, such as anti-PD-1 and anti-PD-L1, becau
245 ghtly to several commonly used neuromuscular blocking agents, such as rocuronium, in aqueous solution
246                                   Cell cycle-blocking agents, synchronization of cells stably express
247 illation was abolished by the sodium channel blocking agent tetrodotoxin (0.1-1 microM).
248 fines potential therapeutic target sites for blocking agents that could interfere with this interacti
249        By using a variety of different nAChR-blocking agents that target specific muscle or neuronal
250                     On day 13, neuromuscular blocking agent therapy was discontinued, but severe prox
251 centration, incubation times and the type of blocking agent to achieve a low limit of detection (LOD)
252 etermined the ability of a selectin receptor blocking agent to affect neutrophil deposition in tissue
253 vine serum albumin (BSA) which served as the blocking agent to prevent non-specific adsorption.
254        Short-chain PDL was further used as a blocking agent to prevent readsorption of the hydrolyzed
255 c interventions in clinical disease by using blocking agents to ameliorate the systemic manifestation
256 c interventions in clinical disease by using blocking agents to ameliorate the systemic manifestation
257 e the capability to administer neuromuscular blocking agents to facilitate intubation (i.e., rapid se
258 e routine administration of an neuromuscular-blocking agents to mechanically ventilated patients with
259  examined the efficacy of two sodium channel blocking agents to protect white matter axons in two for
260           Use of tumor necrosis factor-alpha blocking agents to treat chronic pediatric uveitis is be
261 r treatment guidelines limit the use of HER2-blocking agents to tumors with HER2 gene amplification,
262  out of the sample zone and a small plug of "blocking agent" to negate the cells' mobility and induce
263 ctionalize portions of a gold surface with a blocking agent, typically 1-hexadecanethiol.
264 mportant implications for the safety of CCR5-blocking agents under development for HIV/AIDS.
265 ients had significantly less beta-adrenergic blocking agent use and higher ejection fraction (EF) (p
266  performed to assess whether beta-adrenergic blocking agent use is associated with reduced mortality
267 analysis, the association of beta-adrenergic blocking agent use with reduced mortality remained signi
268 djusting for age, gender and beta-adrenergic blocking agent use, multiple logistic regression analysi
269 or myocardial infarction and beta-adrenergic blocking agent use.
270 e, addiction, epilepsy and for neuromuscular blocking agents used during surgery.
271 ded demographics, sedation and neuromuscular blocking agents used, mechanical ventilation, hemodynami
272 anaesthetized, injected with a neuromuscular blocking agent, vagotomized and artificially ventilated.
273 D. discoideum can be reversed by the channel-blocking agent verapamil.
274 he effects of novel retinoic acid metabolism blocking agent, VN/14-1, in overcoming letrozole resista
275 ty for treatment, receipt of a neuromuscular blocking agent was associated with a reduced risk of in-
276 n to a single cell, an alternative synthetic blocking agent was sought.
277 ion of the CRP system with several different blocking agents was also studied, and 2.0% bovine serum
278                     The use of neuromuscular blocking agents was associated with a lower prevalence o
279                         Use of neuromuscular blocking agents was associated with significantly improv
280 erting enzyme inhibitors and calcium channel blocking agents was determined at discharge for all pati
281 eration in the presence of TNF-alpha or TNFR blocking agents was partially rescued by a TLR2 agonist,
282                             Using cell cycle-blocking agents, we demonstrate that activated T cells a
283 ministration for sedatives and neuromuscular blocking agents were abstracted from ICU flow sheets.
284                              Beta-adrenergic blocking agents were administered concurrently to all pa
285 erting-enzyme inhibitors and beta-adrenergic-blocking agents were administered if the patients could
286                 Interestingly, when integrin-blocking agents were included in these assays, adhesion
287 he no-AAD group, only atrioventricular nodal blocking agents were prescribed.
288                            Various potential blocking agents were screened including salts, polypepti
289 ffects of various gene deletions or chemical blocking agents were tested by investigating the express
290          Patients who received neuromuscular blocking agents were younger (mean age, 62 vs 68), more
291    A short-acting beta1-selective adrenergic blocking agent, when administered during cardiopulmonary
292                     The use of neuromuscular blocking agents, when used by intensivists with a high l
293                              Pharmacological blocking agents which are relatively selective for L- (v
294 nd another segment of solution containing a "blocking agent", which serves to stop the cell migration
295    Total body weight dosing of neuromuscular blocking agents will result in a prolonged effect.
296 gest that coformulation of this transmission-blocking agent with asexual stage antimalarials such as
297                   Sotalol, a beta-adrenergic blocking agent with class III antiarrhythmic properties,
298 ty of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, in chronic h
299 tion for clinical trials combining autophagy-blocking agents with antitumor drugs and radiation.
300 comes of patients treated with neuromuscular blocking agents within the first 2 hospital days to thos

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top